Nicole Junkermann has gradually established itself as a long-term investor in life sciences, with a particular interest in systems, scientific infrastructures and patient capital. In a sector often misunderstood by markets focused on the short term, Nicole Junkermann believes that life sciences are not measured in quarters, but in decades.
Few sectors in the financial markets generate such extreme reactions of enthusiasm and skepticism as the life sciences. Biotechnological advances can transform entire therapeutic categories. However, clinical schedules extend over several years. The regulatory pathways are complex. Failure rates are high.
For investors accustomed to quarterly performance indicators, the sector can seem opaque and unpredictable. But for those willing to think beyond immediate cycles, life sciences represent one of the most compelling grounds for deploying long-term capital.
“Investing in life sciences is fundamentally different from investing in consumer technology,” explains Nicole Junkermannfounder of NJF Capitala specialist venture capital investment firm focused on healthcare and cutting-edge innovation. “It’s not about focusing on a product cycle. It is about rely on science. This requires patience and a different understanding of risk. »
Long-term investment in life sciences: Nicole Junkermann’s point of view
According to Nicole Junkermannthe misunderstanding often begins with the time horizon. Drug development and medical innovation follow biological temporalities, not market cycles. A therapeutic platform may require years of basic research before entering clinical trials. Regulatory approval may take even longer. Early data may seem promising, before being rigorously tested in larger studies.
Short-term investors may find this volatility destabilizing. Long-term capital, on the other hand, sees the opportunity to support systems whose value strengthens over time.
Via NJF Capital, Nicole Junkermann has invested in companies developing AI-driven drug discovery platforms as well as biotechnology companies focused on the biological mechanisms of aging. These are neither speculative operations nor short-term assets. These are structural investments in scientific capacities and research infrastructures.
“The most interesting opportunities are rarely bets on a single asset,” emphasizes Nicole Junkermann. “These are platforms, data infrastructures and research ecosystems that improve the way science is conducted and translated into patient care. These systems create value beyond a single molecule.”
This structural view of life sciences is gaining ground as private capital moves more decisively into the sector. Investors increasingly recognize that advances in oncology, immunology, rare disease research and preventative medicine require sustained funding and institutional support.
Unlike industries driven primarily by consumer demand cycles, life sciences is grounded in demographic and medical reality. Populations are aging. The burden of chronic diseases is increasing. Health systems are under increasing pressure. Scientific innovation is not optional. It is fundamental.
Private markets, patience and scientific infrastructure
Nicole Junkermann observed that listed markets, with their focus on quarterly results and immediate catalysts, often struggle to correctly price scientific uncertainty. The journey that leads from laboratory to patient is rarely linear. Clinical setbacks are part of the research process. Regulatory delays are common.
Private investors with a longer horizon are often better placed to absorb this complexity. They can provide capital aligned to multi-year milestones rather than quarterly reporting schedules.
“Investing in science in the long term implies accepting that progress is iterative,” notes Nicole Junkermann. “We need governance structures that protect the integrity of research, management teams that understand regulatory complexity, and capital aligned with sustained development. »
This alignment is increasingly seen as a competitive advantage. In recent years, more biotech companies have chosen to stay private longer, building up their pipelines and data analytics capabilities before entering public markets. This decision reflects more than just cyclical market conditions. It reflects the recognition that scientific innovation does not naturally align with quarterly expectations.
For investors ready to adopt this horizon, the benefits go beyond financial performance alone. Advances in research supported by machine learning, genomic medicine and regenerative therapies have the potential to transform disease detection and treatments. Their impact can be systemic.
The approach of Nicole Junkermann in terms of investment in life sciences revolves around this long-term transformation. Rather than focusing on individual products, the emphasis is on strengthening the scientific platforms and governance systems that will underpin future standards of care.
In an era where capital often prioritizes speed and liquidity, life sciences stand out. They require conviction. They require patience. And they require investors who can think beyond the next earnings call. Like Nicole Junkermann has regularly maintained, this sector is not inherently volatile or speculative. He simply follows a different rhythm.
